High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide

Bactericidal/permeability-increasing protein (BPI) is a 55-kDa cationic protein (nBPI55) elaborated by polymorphonuclear neutrophils (PMN). BPI has potent bactericidal activity against a wide variety of gram-negative organisms and neutralizes endotoxin activities. An N-terminal fragment of nBPI55 exhibits the bactericidal and antiendotoxin properties of the holoprotein. To further characterize the biological activities of the N-terminal fragment, a recombinant protein (rBPI23) corresponding to the first 199 amino acids of human BPI was produced and purified. rBPI23 had antibacterial activity equivalent to that of nBPI55 against Escherichia coli J5. Furthermore, both rBPI23 and nBPI55 bound identically to a broad range of R- and S-form lipopolysaccharides (LPS) and to natural and synthetic lipid A. Binding of radiolabeled nBPI55 to LPS was inhibited in an identical fashion by either nBPI55 or rBPI23. The binding of both proteins to immobilized E. coli J5 lipid A was inhibited in a comparable fashion by long- or short-chain LPS or lipid A. The binding of both rBPI23 and nBPI55 was specific, saturable, and of high affinity, with an apparent Kd of approximately 2 to 5 nM for all ligands tested. These results demonstrate that BPI recognizes the highly conserved lipid A region of bacterial LPS via residues contained within the amino-terminal portion of the BPI molecule.

[1]  W. Shafer,et al.  Lipid A and resistance of Salmonella typhimurium to antimicrobial granule proteins of human neutrophil granulocytes , 1984, Infection and immunity.

[2]  D. Morrison,et al.  Endotoxic-lipopolysaccharide-specific binding proteins on lymphoid cells of various animal species: association with endotoxin susceptibility , 1989, Infection and immunity.

[3]  D. Morrison,et al.  Lipopolysaccharide nomenclature--past, present, and future , 1986, Journal of bacteriology.

[4]  W. Shafer,et al.  Lipopolysaccharide structure determines ionic and hydrophobic binding of a cationic antimicrobial neutrophil granule protein , 1988, Infection and immunity.

[5]  B. Gray,et al.  Physiological effects of a bactericidal protein from human polymorphonuclear leukocytes on Pseudomonas aeruginosa , 1986, Infection and immunity.

[6]  P. Conlon,et al.  Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides. , 1992, Circulatory shock.

[7]  H. Brade,et al.  The immunogenicity and antigenicity of lipid A are influenced by its physicochemical state and environment , 1987, Infection and immunity.

[8]  R. Ulevitch,et al.  A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. , 1988, The Journal of biological chemistry.

[9]  O. Ramilo,et al.  Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay , 1990, Journal of clinical microbiology.

[10]  R. R. Robinson,et al.  Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. , 1991, Human antibodies and hybridomas.

[11]  R. Ulevitch,et al.  Structure and function of lipopolysaccharide binding protein. , 1990, Science.

[12]  P. Elsbach,et al.  The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. , 1984, Journal of immunology.

[13]  Richard Axel,et al.  Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells , 1977, Cell.

[14]  P. Elsbach,et al.  Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure. , 1980, The Journal of clinical investigation.

[15]  I. Olsson,et al.  Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. , 1987, Blood.

[16]  R. Ulevitch,et al.  Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum , 1986, The Journal of experimental medicine.

[17]  H. Brade,et al.  Structure-activity relationships of bacterial lipopolysaccharides (endotoxins). Current and future aspects. , 1988, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.

[18]  W. Shafer,et al.  Antimicrobial binding of a radiolabeled cationic neutrophil granule protein , 1987, Infection and immunity.

[19]  M A Markwell,et al.  A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. , 1982, Analytical biochemistry.

[20]  D. Morrison The case for specific lipopolysaccharide receptors expressed on mammalian cells. , 1989, Microbial pathogenesis.

[21]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[22]  R. Munford,et al.  Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme. , 1986, Science.

[23]  M. N. Marra,et al.  Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. , 1990, Journal of Immunology.

[24]  C. E. Ooi,et al.  A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. , 1987, The Journal of biological chemistry.

[25]  J. Spitznagel,et al.  Antibiotic proteins of human neutrophils. , 1990, The Journal of clinical investigation.

[26]  H. Odeberg,et al.  Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. , 1978, The Journal of biological chemistry.

[27]  M. Hutzler,et al.  Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein , 1986, Infection and immunity.

[28]  F. Ognibene,et al.  Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. , 1990, Annals of internal medicine.

[29]  W. Shafer,et al.  Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of diisopropyl fluorophosphate , 1984, Infection and immunity.

[30]  P. Elsbach,et al.  Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. , 1989, Journal of immunology.

[31]  D. Morrison,et al.  Endotoxins and disease mechanisms. , 1987, Annual review of medicine.

[32]  P. Conlon,et al.  Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides. , 1992, Circulatory shock.

[33]  C. Raetz,et al.  Biochemistry of endotoxins. , 1990, Annual review of biochemistry.

[34]  R. Ulevitch,et al.  Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. , 1989, The Journal of biological chemistry.

[35]  M. Doerfler,et al.  Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils , 1991, The Journal of experimental medicine.

[36]  A. Schneider,et al.  Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. , 1979, The Journal of biological chemistry.

[37]  C. E. Ooi,et al.  Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. , 1989, The Journal of biological chemistry.

[38]  R. Koduri,et al.  Expression of synthetic thaumatin genes in yeast. , 1988, Biochemistry.

[39]  M. N. Marra,et al.  The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. , 1992, Journal of immunology.